Home LiteratureArticle Details
PMID: 18850007 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.

Oncogene ·Vol. 28 ·No. 2 ·2009-01-15 ·Pages 184-94

Lee SH, Kim J, Kim WH, Lee YM

Abstract

RUNX3 is a tumor suppressor that is silenced in cancer following hypermethylation of its promoter. The effects of hypoxia in tumor suppressor gene (TSG) transcription are largely unknown. Here, we investigated hypoxia-induced silencing mechanisms of RUNX3. The expression of RUNX3 was downregulated in response to hypoxia in human gastric cancer cells at the transcriptional level. This downregulation was abolished following treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) and cytosine methylation inhibitor 5-aza-2-deoxycytidine (5-Aza), suggesting that an epigenetic regulatory mechanism may be involved in RUNX3 silencing by hypoxia. DNA methylation PCR and bisulfite-sequencing data revealed that hypoxia did not affect the methylation of RUNX3 promoter. A chromatin immunoprecipitation (ChIP) assay revealed increased histone H3-lysine 9 dimethylation and decreased H3 acetylation in the RUNX3 promoter following hypoxia. Hypoxia resulted in the upregulation of G9a histone methyltransferase (HMT) and HDAC1; additionally, overexpression of G9a and HDAC1 attenuated RUNX3 expression. The overexpression of G9a and HDAC1, but not their mutants, inhibited the nuclear localization and expression of RUNX3. Diminished mRNA expression and nuclear localization of RUNX3 during hypoxia was abolished by siRNA-mediated knockdown of G9a and HDAC1. This study suggests that hypoxia silences RUNX3 by epigenetic histone regulation during the progression of gastric cancer.

MeSH Terms
Acetylation/drug effects Azacitidine/analogs & derivatives,pharmacology Cell Hypoxia/genetics Cell Line, Tumor/drug effects,metabolism Core Binding Factor Alpha 3 Subunit/antagonists & inhibitors,metabolism DNA Methylation/drug effects Decitabine Disease Progression Down-Regulation Epigenesis, Genetic/drug effects Gene Expression Regulation, Neoplastic/drug effects,genetics Gene Silencing Genes, Tumor Suppressor/drug effects Histocompatibility Antigens/physiology Histone Deacetylase 1 Histone Deacetylase Inhibitors Histone Deacetylases/physiology Histone-Lysine N-Methyltransferase/physiology Humans Hydroxamic Acids/pharmacology Methylation/drug effects Neoplasm Proteins/antagonists & inhibitors,metabolism Protein Processing, Post-Translational/drug effects Recombinant Fusion Proteins/physiology Stomach Neoplasms/genetics,metabolism,pathology Transcription, Genetic
Chemicals
Core Binding Factor Alpha 3 Subunit Histocompatibility Antigens Histone Deacetylase Inhibitors Hydroxamic Acids Neoplasm Proteins Recombinant Fusion Proteins Runx3 protein, human trichostatin A Decitabine EHMT2 protein, human Histone-Lysine N-Methyltransferase HDAC1 protein, human Histone Deacetylase 1 Histone Deacetylases Azacitidine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Lee S H
Department of Natural Sciences, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu, Republic of Korea.
Kim J
Kim W-H
Lee Y M
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
1476-5594
Published
2009-01-15
Epub
2008-00-13
Pages
184-94
Language
English
Region
England
NLM ID
8711562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]